STOCK TITAN

Smith & Nephew plc - SNN STOCK NEWS

Welcome to our dedicated page for Smith & Nephew plc news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew plc stock.

Smith & Nephew plc, also known as Smith+Nephew, is a leading British multinational medical equipment manufacturing company headquartered in Watford, England. Established in 1856, this pioneering firm excels in designing, manufacturing, and marketing advanced medical devices and technologies. Their core business areas include orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions.

Smith+Nephew's revenue is diversified across three main segments: Orthopedics (41%), Sports Medicine and ENT (30%), and Advanced Wound Therapy (29%). The United States contributes roughly half of the company’s total revenue, with other developed markets accounting for over 30%, and the remaining portion coming from emerging markets. The company operates in more than 100 countries and generated annual sales of $5.2 billion in 2022.

Recently, Smith+Nephew celebrated a significant milestone by receiving 510(k) clearance from the U.S. FDA for the AETOS Shoulder System. This advanced system is designed to enhance surgical experiences through greater intraoperative flexibility and fewer conversion steps and instruments, simplifying the operating room flow. The AETOS Shoulder System is part of the company's expanding Upper Extremity portfolio and complements its market-leading Sports Medicine shoulder repair and biologics solutions.

Another notable achievement includes the standout results of the REGENETEN Bioinductive Implant from a randomized controlled trial. This innovative implant substantially reduced re-tear rates in rotator cuff repairs, showcasing Smith+Nephew's commitment to improving patient outcomes through evidence-based solutions.

Smith+Nephew has also entered into a groundbreaking Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This agreement allows for collaborative research across all business units, fostering innovation and enhancing combat casualty care.

Moreover, the company launched the RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US, which is a patient-centric option for treating chronic wounds. This system is designed for easy portability and quiet operation, making it suitable for patients' daily activities.

Smith+Nephew's purpose, 'Life Unlimited,' reflects their mission to help restore people's bodies and self-belief by using technology to enhance living. With 19,000 dedicated employees, the company continues to innovate and improve the quality of life for patients worldwide.

For more information about Smith+Nephew, please visit their official website and follow them on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.

Rhea-AI Summary

Smith+Nephew (NYSE:SNN) has announced the launch of its expanded Extremities portfolio at the American Academy of Orthopaedic Surgeons 2021 Annual Meeting in San Diego. This portfolio results from acquiring Integra LifeSciences' Extremity Orthopaedics business and features solutions for upper and lower extremity arthritis and fracture management. Notably, two products, the CADENCE Total Ankle Flat Cut Talar Dome System and the ATLASplan Shoulder 3D Planning System, were highlighted, aiming to enhance surgical efficiency and accuracy. The CADENCE system is targeted at treating end-stage ankle arthritis, while the ATLASplan software aims to improve shoulder surgical precision.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary

Smith+Nephew (LSE:SN, NYSE:SNN) announced new findings for its OR3O Dual Mobility Hip System and OXINIUM DH Technology at the AAOS 2021 Annual Meeting. Data demonstrates a significant reduction in material loss and corrosion in OXINIUM DH liners compared to CoCrMo liners. In-vitro tests indicated a substantial difference in metal ion elution, addressing concerns over CoCrMo implants. This technology, launched in 2019, captures 12% of primary hip replacements and 30% of revisions in the U.S., positioning Smith+Nephew as a competitive leader in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
Rhea-AI Summary

Smith+Nephew (NYSE:SNN) has launched the WEREWOLF FASTSEAL 6.0 Hemostasis Wand, enhancing its radio-frequency technology for orthopaedic reconstruction. This innovation aims to aid surgeons by reducing blood loss and procedure time during total joint arthroplasty. The device's integration into the existing WEREWOLF platform allows for versatile use across specialties. Surgeon Ronald W. Singer praised its efficiency and ease of use. The launch underscores Smith+Nephew's commitment to advancing medical technology while improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
Rhea-AI Summary

Smith+Nephew (NYSE:SNN) revealed study results at the AOSSM-AANA Combined 2021 Annual Meeting showing its REGENETEN Bioinductive Implant significantly improved early recovery in patients with partial-thickness rotator cuff tears compared to traditional surgical repair. The study, involving 227 patients, found that those treated with the implant alone reported better shoulder function at 2 and 6 weeks post-operation, with equivalent efficacy at one year. The implant is minimally invasive and resorbs within six months, supporting tissue growth and recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary

Smith+Nephew (NYSE:SNN) has launched the FAST-FIX FLEX Meniscal Repair System, a breakthrough device featuring a surgeon-guided, bendable needle that enhances access to all meniscal zones. This innovation potentially increases repair rates over removal, addressing over 400,000 procedures annually in the U.S. The system boasts a 25% reduction in needle insertion area and stronger repairs. It is designed to improve procedural efficiency and minimize the need for incisions, ultimately aiming to shift the standard of care from meniscectomy to meniscal repair.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary

Smith+Nephew (NYSE:SNN) has launched ARIA Home PT, a remote physical therapy solution that enhances patient care by providing customized experiences and actionable data. The product significantly reduces healthcare costs, with an average savings of $2,745 per patient, while decreasing readmissions (60%) and outpatient visits (86%). ARIA Home PT leverages advanced technology and telehealth, improving patient adherence by 35% and achieving a Net Promoter Score of 90.3. The launch addresses growing demand for physical therapy amid a projected therapist shortage by 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
Rhea-AI Summary

Smith+Nephew (NYSE:SNN) published research indicating that 45% of clinicians believe their patients with chronic wounds would benefit from more involvement in their care, which can free up time for additional patients. The study, published in Wounds International, highlighted the role of COVID-19 in increasing remote care and patient engagement through digital tools. Despite positive feedback about shared care approaches in regions like the USA and UK, clinicians expressed the need for support in identifying suitable patients for shared care. The research involved 511 healthcare practitioners globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
covid-19
-
Rhea-AI Summary

Smith+Nephew (LSE: SN, NYSE: SNN) announces a study demonstrating that its computer-guided technology for total hip arthroplasty (THA), known as RI.HIP NAVIGATION, significantly lowers revision rates and enhances patient satisfaction. Utilizing the National Joint Registry of England, Wales, and Northern Ireland, the study found a 55% lower risk of revision at ten years (1.06% vs. 3.88% for conventional THA). Higher patient satisfaction rates were also reported in the computer-guided group. This technology aims to improve long-term outcomes for patients undergoing hip replacement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary

Smith+Nephew (NYSE:SNN) announces the launch of DOUBLEFLO Inflow/Outflow Pump and 4KO (Optimized) Arthroscopes and Laparoscopes, enhancing the INTELLIO Connected Tower Solution. The DOUBLEFLO Pump is remotely controllable, allowing surgeons to focus on patients during procedures. The 4KO Scopes promise a 30% increase in image resolution, supporting multi-specialty centers. Both products are now available in the US and Europe, aimed at improving surgical performance and capital investment value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
Rhea-AI Summary

Smith+Nephew (LSE:SN, NYSE:SNN) announced that its LEAF Patient Monitoring System has monitored over 60,000 patients, accumulating more than 7 million hours of use. This system aims to reduce hospital-acquired pressure injuries (HAPIs), which have risen in the U.S., costing an average of $21,767 per patient. Clinical trials indicated a 73% reduction in HAPI odds, potentially saving up to $39 billion nationally. By implementing the LEAF System, healthcare facilities have raised patient repositioning adherence from under 50% to as high as 98%, enhancing patient care and reducing costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags

FAQ

What is the current stock price of Smith & Nephew plc (SNN)?

The current stock price of Smith & Nephew plc (SNN) is $24.54 as of December 23, 2024.

What is the market cap of Smith & Nephew plc (SNN)?

The market cap of Smith & Nephew plc (SNN) is approximately 10.7B.

What does Smith & Nephew specialize in?

Smith & Nephew specializes in orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions.

Where is Smith & Nephew headquartered?

Smith & Nephew is headquartered in Watford, England.

What are the main revenue segments of Smith & Nephew?

The main revenue segments are Orthopedics (41%), Sports Medicine and ENT (30%), and Advanced Wound Therapy (29%).

What recent achievement has Smith & Nephew made in orthopedic technology?

Smith & Nephew recently received 510(k) clearance from the U.S. FDA for the AETOS Shoulder System.

How does the REGENETEN Bioinductive Implant benefit patients?

The REGENETEN Bioinductive Implant significantly reduces re-tear rates in rotator cuff repairs, improving patient outcomes.

What is the purpose of Smith & Nephew's Master CRADA with the USAISR?

The Master CRADA aims to facilitate collaborative research across all business units, enhancing combat casualty care.

What is unique about the RENASYS EDGE NPWT System?

The RENASYS EDGE NPWT System is lightweight, portable, and operates quietly, making it ideal for patients' daily activities.

What is Smith & Nephew's company mission?

Smith & Nephew's mission is 'Life Unlimited,' focusing on restoring people's bodies and self-belief through advanced technology.

How many countries does Smith & Nephew operate in?

Smith & Nephew operates in more than 100 countries.

How can I learn more about Smith & Nephew?

For more information, visit their official website and follow them on social media platforms like Twitter, LinkedIn, Instagram, and Facebook.

Smith & Nephew plc

NYSE:SNN

SNN Rankings

SNN Stock Data

10.73B
435.58M
0.03%
7.55%
0.71%
Medical Devices
Healthcare
Link
United States of America
Watford